Month: January 2021

Strong financial performance with free cash flow generation of MUSD 448, operating cost below guidance at USD 2.69 per boe and reduced net debt to USD 3.9 billionBalance sheet re-financed with USD 5 billion corporate facility with significantly improved termsBoard of Directors propose to increase 2020 dividend by 80 percent to USD 1.80 per share corresponding to MUSD 512Record quarterly production in the fourth quarter of 185 Mboepd and 2021 production guidance set between 170 to 190 MboepdJohan Sverdrup Phase 1 plateau production raised to 500 Mbopd gross, with expectation to increase up to 535 Mbopd by mid-2021Edvard Grieg reserves increased by 50 MMboe to 350 MMboe gross 2P ultimate recovery, extending plateau a further year to late 2023Delivering growth with resource additions of 210 percent of production in 2020 and pipeline of new...

Starka finansiella resultat med fritt kassaflöde om 448 MUSD, verksamhetskostnader under prognos om 2,69 USD per boe och minskad nettoskuld om 3,9 miljarder USDKreditfacilitet om 5 miljarder USD refinansierad till betydligt förbättrade villkorStyrelsen föreslår ökad utdelning för 2020 med 80 procent till 1,80 USD per aktie, motsvarande 512 MUSDRekordhög produktion för det fjärde kvartalet om 185 Mboepd, och produktionsprognos för 2021 som uppgår till mellan 170 och 190 MboepdPlatåproduktion för Johan Sverdrups första fas ökad till 500 Mbopd, brutto och förväntas öka upp till 535 Mbopd vid mitten av 2021Reservökning med 50 MMboe för Edvard Grieg, vilket tar fältets slutliga utvinningsbara 2P reserver till 350 MMboe, brutto och förlänger platåproduktionen med ytterligare ett år till slutet av 2023Tillväxt levererad i form av resursökning...

CONSTI PLC STOCK EXCHANGE RELEASE 28 JANUARY 2021, at 08.30 a.m.Change in Consti’s Management Team: Jukka Kylliö appointed as Business Area Director of Public SectorJukka Kylliö (born 1967, B.Eng., CPM®) has been appointed as Business Area Director of Public Sector and a member of Consti’s Management Team. Kylliö has most recently acted as Regional Director at Skanska Talonrakennus Oy. He has a long career in various management and project development positions at NCC Rakennus Oy and Lemminkäinen Group in the non-residential construction sector.Jukka Kylliö will assume his position as member of Consti Plc’s Management Team on 4 February 2021 and he will report to Esa Korkeela, CEO of Consti Group.“I warmly welcome Jukka to Consti. He has a deep knowledge of our industry and business, and with the right kind of expertise he is capable...

CONSTI OYJ PÖRSSITIEDOTE 28.1.2021, KLO 08.30Muutos Constin johtoryhmässä: Jukka Kylliö nimitetty Julkiset-toimialan johtoonJukka Kylliö (s.1967, RI, KJs) on nimitetty Julkiset-toimialan toimialajohtajaksi ja Consti Oyj:n johtoryhmän jäseneksi. Kylliö on viimeksi toiminut aluejohtajana Skanska Talonrakennus Oy:n palveluksessa. Hänellä on pitkä ura erilaisissa toimitilarakentamisen johto- ja hankekehitystehtävissä myös NCC Rakennus Oy:n ja Lemminkäinen-konsernin palveluksessa.Jukka Kylliö aloittaa Consti Oyj:n johtoryhmän jäsenenä 4.2.2021 ja hän raportoi toimitusjohtaja Esa Korkeelalle.“Toivotan Jukan lämpimästi tervetulleeksi Constille. Hänellä on syvä asiantuntemus toimialastamme ja liiketoiminnastamme, ja hän pystyy oikeanlaisella osaamisellaan tukemaan Constin kasvua sekä tuottavuuden ja kannattavuuden parantamista. Jukan johdolla...

 Geneva, Switzerland and Boston, MA – Thursday 28 January, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, announced today that its board of directors approved on January 27, 2021 an increase of its share capital from 60,202,619 to 66,222,867 through the issuance of 6,020,248 new registered shares at an issue price of 1/13 of a Swiss Franc each. The 6,020,248 new shares, to be issued out of the company’s authorized capital, will be fully subscribed for by ObsEva USA Inc., its 100% wholly owned subsidiary, and listed on the SIX Swiss Exchange on or around February 2, 2021. The transaction has been decided to provide the group with additional...

Vaccine production initiated to optimize timeline for potential deliveriesPhase 1/2 clinical study now fully enrolled; initial data read out expected in April 2021Saint-Herblain (France), January 28, 2021 – Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced it has commenced production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies, in order to optimize the timeline for potential deliveries of the vaccine. The Phase 1/2 clinical study is now fully enrolled and is expected to report initial results in April 2021.VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. A total of 150 healthy adults aged 18 to 55 years have been recruited for the Phase...

Production du vaccin initiée pour optimiser le calendrier des livraisons potentiellesRecrutement finalisé pour l’étude de Phase 1/2; premiers résultats attendus en avril 2021Saint-Herblain (France), 28 janvier 2021 – Valneva SE, société spécialisée dans les vaccins contre les maladies infectieuses générant d’importants besoins médicaux, a annoncé aujourd’hui avoir initié la production de son candidat vaccin inactivé et adjuvanté contre la COVID-19, en parallèle des études cliniques actuellement en cours, en vue d’optimiser le calendrier des livraisons potentielles du vaccin. Le recrutement des participants à l’étude de Phase 1/2 a par ailleurs été achevé et les premiers résultats de l’étude sont attendus en avril 2021.VLA2001 est actuellement le seul candidat vaccin à virus inactivé contre la COVID-19 en développement clinique en Europe....

Lassila & Tikanoja plcStock exchange release28 January 2021 at 08:00 a.m.Lassila & Tikanoja plc: Financial Statements 1 January–31 December 2020GOOD PERFORMANCE IN EXCEPTIONAL CIRCUMSTANCESUnless otherwise mentioned, the figures in brackets refer to the corresponding period in the previous year.Net sales for the final quarter were EUR 199.6 million (198.9), operating profit was EUR 9.9 million (8.9) and adjusted operating profit was EUR 9.9 million (9.5)*. Earnings per share were EUR 0.20 (0.16).Net sales for 2020 were EUR 751.9 million (784.3), operating profit was EUR 28.2 million (45.0) and adjusted operating profit was EUR 39.0 million (40.5)*. Earnings per share were EUR 0.50 (0.90). Operating profit and earnings per share were negatively affected by costs of EUR 9.0 million recognised in relation to the discontinuation...